Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

Search Results

556 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Results By Year timeline is not available.
Page 1
Ribavirin in chronic hepatitis C: past and future.
Loustaud-Ratti V, Rousseau A, Marquet P, Denis F, Alain S. Loustaud-Ratti V, et al. Among authors: marquet p. Expert Rev Anti Infect Ther. 2009 Apr;7(3):249-53. doi: 10.1586/eri.09.5. Expert Rev Anti Infect Ther. 2009. PMID: 19344238 No abstract available.
Pharmacological exposure to ribavirin: a key player in the complex network of factors implicated in virological response and anaemia in hepatitis C treatment.
Loustaud-Ratti V, Carrier P, Rousseau A, Maynard M, Babany G, Alain S, Trépo C, De Ledinghen V, Bourlière M, Pol S, Di Martino V, Zarski JP, Pinta A, Sautereau D, Marquet P; OPTIRIB group. Loustaud-Ratti V, et al. Among authors: marquet p. Dig Liver Dis. 2011 Nov;43(11):850-5. doi: 10.1016/j.dld.2011.04.002. Epub 2011 May 18. Dig Liver Dis. 2011. PMID: 21596633 Review.
Ribavirin therapeutic drug monitoring: why, when and how?
Stanke-Labesque F, Loustaud-Ratti V, Babany G, Gagnieu MC, Marquet P; French Ribavirin Group OPTIRIB. Stanke-Labesque F, et al. Among authors: marquet p. Fundam Clin Pharmacol. 2010 Aug;24(4):401-6. doi: 10.1111/j.1472-8206.2009.00778.x. Epub 2009 Sep 24. Fundam Clin Pharmacol. 2010. PMID: 19788564 Review.
Efficiency and Safety of an Early Dose Adjustment of Ribavirin in Patients Infected With Hepatitis C Underexposed to the Drug and Treated With Peginterferon Ribavirin.
Loustaud-Ratti V, Maynard M, Thevenon S, Pradat P, Rousseau A, Alain S, Deny P, Gagnieu MC, Tran A, Dao T, Silvain C, Lunel-Fabiani F, Picard N, Zublena I, Marquet P, Trepo C; RIBAJUSTE Group. Loustaud-Ratti V, et al. Among authors: marquet p. Ther Drug Monit. 2016 Dec;38(6):684-692. doi: 10.1097/FTD.0000000000000332. Ther Drug Monit. 2016. PMID: 27559840 Clinical Trial.
Ribavirin: Past, present and future.
Loustaud-Ratti V, Debette-Gratien M, Jacques J, Alain S, Marquet P, Sautereau D, Rousseau A, Carrier P. Loustaud-Ratti V, et al. Among authors: marquet p. World J Hepatol. 2016 Jan 18;8(2):123-30. doi: 10.4254/wjh.v8.i2.123. World J Hepatol. 2016. PMID: 26807208 Free PMC article. Review.
Optimizing ribavirin dosage: a new challenge to improve treatment efficacy in genotype 1 hepatitis C patients.
Loustaud-Ratti V, Stanke-Labesque F, Marquet P, Gagnieu MC, Maynard M, Babany G, Trépo C; French Ribavirin Group OPTIRIB. Loustaud-Ratti V, et al. Among authors: marquet p. Gastroenterol Clin Biol. 2009 Jun-Jul;33(6-7):580-3. doi: 10.1016/j.gcb.2009.04.009. Epub 2009 May 28. Gastroenterol Clin Biol. 2009. PMID: 19481390 Free article. No abstract available.
HCV-associated B-cell non-Hodgkin lymphomas and new direct antiviral agents.
Carrier P, Jaccard A, Jacques J, Tabouret T, Debette-Gratien M, Abraham J, Mesturoux L, Marquet P, Alain S, Sautereau D, Essig M, Loustaud-Ratti V. Carrier P, et al. Among authors: marquet p. Liver Int. 2015 Oct;35(10):2222-7. doi: 10.1111/liv.12897. Epub 2015 Jul 15. Liver Int. 2015. PMID: 26104059
556 results